| REPLIMUNE GR. INC DL-,001 |
| USA |
| Gesundheit |
| US76029N1063 / A2JQN1 |
| 7R8 (Frankfurt) / REPL (NASDAQ) |
| FRA:7R8, ETR:7R8, 7R8:GR, NASDAQ:REPL |
| - |
| https://replimune.com/ |
|
Replimune Group Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies to treat cancer. These therapies use genetically modified viruses to selectively target and kill tumor cells, while simultaneously stimulatin..
>Volltext.. |
| 603.89 Mio. EUR |
| 441.66 Mio. EUR |
| - |
| -275.58 Mio. EUR |
| -269.63 Mio. EUR |
| -3.07 EUR |
| 65.38 Mio. EUR |
| 105.29 Mio. EUR |
| -238 Mio. EUR |
| 5.37 |
| - |
| -21.59% |
| - |
| - |
| - |
| REPLIMUNE |
| 08.04.26 |
|